A share price of Denali Therapeutics Inc [DNLI] is currently trading at $25.60, up 3.35%. An important factor to consider is whether the stock is rising or falling in short-term value. The DNLI shares have gain 6.89% over the last week, with a monthly amount glided 6.22%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Denali Therapeutics Inc [NASDAQ: DNLI] stock has seen the most recent analyst activity on December 13, 2023, when Citigroup initiated its Buy rating and assigned the stock a price target of $32. B. Riley Securities started tracking the stock assigning a Buy rating and suggested a price target of $38 on September 06, 2023. SVB Securities initiated its recommendation with a Outperform and recommended $50 as its price target on January 30, 2023. In a note dated November 02, 2022, BTIG Research upgraded an Buy rating on this stock but restated the target price of $38.
Denali Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $14.56 and $25.34. Currently, Wall Street analysts expect the stock to reach $91 within the next 12 months. Denali Therapeutics Inc [NASDAQ: DNLI] shares were valued at $25.60 at the most recent close of the market. An investor can expect a potential return of 255.47% based on the average DNLI price forecast.
Analyzing the DNLI fundamentals
Trailing Twelve Months sales for Denali Therapeutics Inc [NASDAQ:DNLI] were 1.27M which represents -100.00% decline. Gross Profit Margin for this corporation currently stands at 1.03% with Operating Profit Margin at 1.63%, Pretax Profit Margin comes in at 1.38%, and Net Profit Margin reading is 1.38%. To continue investigating profitability, this company’s Return on Assets is posted at -0.28, Equity is -0.34 and Total Capital is -0.35. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 25.10 points at the first support level, and at 24.60 for the second support level. However, for the 1st resistance point, the stock is sitting at 26.00, and for the 2nd resistance point, it is at 26.40.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Denali Therapeutics Inc [NASDAQ:DNLI] is 12.46. On the other hand, the Quick Ratio is 12.46, and the Cash Ratio is 1.0. Considering the valuation of this stock, the price to sales ratio is 2885.74, the price to book ratio is 2.64.
Transactions by insiders
Recent insider trading involved Watts Ryan J., President and CEO, that happened on Aug 20 ’24 when 2260.0 shares were sold. Director, Krognes Steve E. completed a deal on Aug 20 ’24 to sell 1727.0 shares. Meanwhile, COFO and Secretary Schuth Alexander O. sold 5806.0 shares on Aug 20 ’24.
